You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Niraparib

Showing 26 - 50 of 186
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

HRD, Cholangiocarcinoma, Metastatic Cancer Trial (Niraparib, Dostarlimab)

Withdrawn
  • HRD
  • +2 more
  • (no location specified)
Jun 23, 2022

Tumors Trial in United States (Niraparib Tablet, Niraparib Capsule)

Active, not recruiting
  • Neoplasms
  • Niraparib Tablet
  • Niraparib Capsule
  • Encinitas, California
  • +15 more
Sep 7, 2022

Metastatic Pancreatic Cancer Trial in Lyon (Niraparib)

Not yet recruiting
  • Metastatic Pancreatic Cancer
  • Niraparib
  • Lyon, France
    Centre Léon Bérard
Jul 4, 2022

Recurrent Endometrial Serous Adenocarcinoma Trial in Columbus (procedure, biological, drug)

Not yet recruiting
  • Recurrent Endometrial Serous Adenocarcinoma
  • Biospecimen Collection
  • +4 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
May 12, 2023

Recurrent Ovarian Cancer, Recurrent Fallopian Tube Cancer, Primary Peritoneal Cancer Trial (Niraparib, Dostarlimab)

Not yet recruiting
  • Recurrent Ovarian Cancer
  • +2 more
  • (no location specified)
Jul 26, 2022

Solid Tumor Trial in Belgium, Netherlands, United Kingdom (SYD985 + Niraparib)

Active, not recruiting
  • Solid Tumor
  • SYD985 + Niraparib
  • Antwerp, Belgium
  • +5 more
Jan 23, 2023

Locally Advanced Leiomyosarcoma, Metastatic Leiomyosarcoma, Stage III Retroperitoneal Sarcoma AJCC v8 Trial in Columbus

Not yet recruiting
  • Locally Advanced Leiomyosarcoma
  • +6 more
  • Niraparib Tosylate Monohydrate
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Jul 25, 2022

Esophageal Cancer, Gastric Cancer, Adenocarcinoma Trial in United States (Niraparib)

Recruiting
  • Esophageal Cancer
  • +2 more
  • Niraparib
  • Tampa, Florida
  • +3 more
Jan 18, 2023

Rectal Tumors, Rectal Tumor Malignant Trial in Iowa City (Niraparib, Dostarlimab, Short course radiation)

Recruiting
  • Rectal Neoplasms
  • Rectal Neoplasm Malignant
  • Niraparib
  • +2 more
  • Iowa City, Iowa
    Holden Comprehensive Cancer Center at the University of Iowa
Jul 22, 2022

Ovarian Cancer, Resistant BRCA Wild-Type Ovarian Cancer Trial in Birmingham (Cohort 1: Dose Escalation, Cohort 2: Dose

Terminated
  • Ovarian Cancer
  • Resistant BRCA Wild-Type Ovarian Cancer
  • Cohort 1: Dose Escalation
  • Cohort 2: Dose Escalation
  • Birmingham, Alabama
    University of Alabama at Birmingham
Apr 29, 2022

Ovarian Carcinoma, Survival Outcomes, Adverse Events Trial in Beijing (Niraparib plus anlotinib)

Recruiting
  • Ovarian Carcinoma
  • +8 more
  • Niraparib plus anlotinib
  • Beijing, Beijing, China
    Lei Li
Apr 5, 2022

Niraparib in Treatment of Adult Approved Indications in South

Recruiting
  • Ovarian Neoplasms
    • Busan, Korea, Republic of
      Inje University Haeundae Paik Hospital
    Oct 19, 2022

    Homologous Recombination Deficiency, Triple Negative Breast Cancer Trial (Niraparib)

    Not yet recruiting
    • Homologous Recombination Deficiency
    • Triple Negative Breast Cancer
    • Niraparib
    • (no location specified)
    Jul 15, 2022

    Metastatic Carcinoma of the Cervix Trial in Houston (Nirapaib)

    Suspended
    • Metastatic Carcinoma of the Cervix
    • Houston, Texas
    • +2 more
    Dec 7, 2022

    Metastatic Solid Tumor, BRCA1 Mutation, BRCA2 Mutation Trial in San Francisco (Niraparib, Irinotecan)

    Not yet recruiting
    • Metastatic Solid Tumor
    • +4 more
    • San Francisco, California
      University of California, San Francisco
    Jan 12, 2023

    Ovarian Tumor Trial in United States (Dostarlimab, Bevacizumab, Niraparib)

    Completed
    • Ovarian Neoplasm
    • Birmingham, Alabama
    • +9 more
    Feb 20, 2023

    Metastatic Breast Cancer, HER2 Positive Breast Carcinoma Trial in United States (Niraparib, Trastuzumab)

    Recruiting
    • Metastatic Breast Cancer
    • HER2 Positive Breast Carcinoma
    • Birmingham, Alabama
    • +6 more
    Dec 13, 2022

    Breast Cancer, Breast Cancer Metastatic Trial in Spain (Niraparib 100 MG, Aromatase Inhibitors)

    Terminated
    • Breast Cancer
    • Breast Cancer Metastatic
    • Niraparib 100 MG
    • Aromatase Inhibitors
    • A Coruña, Spain
    • +9 more
    Jan 17, 2023

    Recurrent Glioblastoma, Recurrent Astrocytoma, Recurrent Oligodendroglioma Trial in Oklahoma City (Niraparib)

    Recruiting
    • Recurrent Glioblastoma
    • +3 more
    • Niraparib
    • Oklahoma City, Oklahoma
      Stephenson Cancer Center
    Jul 20, 2022

    Pancreatic Adenocarcinoma Trial in Philadelphia (Niraparib + Nivolumab, Niraparib + Ipilimumab)

    Active, not recruiting
    • Pancreatic Adenocarcinoma
    • Niraparib + Nivolumab
    • Niraparib + Ipilimumab
    • Philadelphia, Pennsylvania
      University of Pennsylvania, Abramson Cancer Center
    Mar 23, 2022

    Breast Cancer Trial (Niraparib, Doxorubicin, Cyclophosphamide)

    Withdrawn
    • Breast Cancer
    • Niraparib
    • +5 more
    • (no location specified)
    Apr 20, 2022

    Tumors Trial in United States (Niraparib, Pembrolizumab, TSR-042 (Dostarlimab))

    Completed
    Has Results
    • Neoplasms
    • Niraparib
    • +2 more
    • Whittier, Alaska
    • +15 more
    Aug 29, 2022

    Tumors Trial in France, Spain, United Kingdom (Niraparib, Dostarlimab)

    Recruiting
    • Neoplasms
    • Brno, Czechia
    • +20 more
    Nov 21, 2022

    Metastatic Colorectal Cancer Trial (Niraparib)

    Not yet recruiting
    • Metastatic Colorectal Cancer
    • Niraparib
    • (no location specified)
    Jun 7, 2022

    Epithelial Ovarian Cancer Trial (Niraparib)

    Not yet recruiting
    • Epithelial Ovarian Cancer
    • Niraparib
    • (no location specified)
    May 19, 2022